Literature DB >> 1689190

Human granulocyte colony-stimulating factor: biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines.

B R Avalos1, J C Gasson, C Hedvat, S G Quan, G C Baldwin, R H Weisbart, R E Williams, D W Golde, J F DiPersio.   

Abstract

Human granulocyte colony-stimulating factor (G-CSF) is a regulatory glycoprotein that stimulates the production of neutrophilic granulocytes from committed hematopoietic progenitor cells both in vitro and in vivo. In this report, we show that biosynthetic (recombinant) human G-CSF enhances colony formation by normal human bone marrow and the human myeloid leukemic cell lines, HL-60 and KG-1, as well as nonhematopoietic small cell lung cancer lines, H128 and H69. G-CSF also modulates multiple differentiated functions of human neutrophils, including enhanced oxidative metabolism in response to f-Met-Leu-Phe (f-MLP), increased antibody-dependent cell-mediated cytotoxicity (ADCC), and augmented arachidonic acid release in response to ionophore and chemotactic agents. These effects are all maximal at a concentration of 100 to 500 pmol/L. Using 125I-labeled recombinant human G-CSF, high affinity binding sites were identified on human neutrophils, the myeloid leukemia cell lines KG-1 and HL-60, and the small cell carcinoma cell lines, H128 and H69. G-CSF receptor numbers ranged between 138 and 285 sites per cell with a kd of 77 to 140 pmol/L, consistent with the concentrations of G-CSF that elicit biologic responses in vitro. Decreased specific binding of 125l-G-CSF by human neutrophils was consistently observed in the presence of excess unlabeled human granulocyte-macrophage colony-stimulating factor (GM-CSF), suggesting competition or down modulation by GM-CSF of the G-CSF receptor.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689190

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  38 in total

Review 1.  New perspectives in lung cancer. 4. Haematopoietic growth factors and lung cancer treatment.

Authors:  N Thatcher
Journal:  Thorax       Date:  1992-02       Impact factor: 9.139

Review 2.  New perspectives in lung cancer. 2. Growth factors and lung cancer.

Authors:  P J Woll
Journal:  Thorax       Date:  1991-12       Impact factor: 9.139

3.  NETosis promotes cancer-associated arterial microthrombosis presenting as ischemic stroke with troponin elevation.

Authors:  Charlotte Thålin; Melanie Demers; Bo Blomgren; Siu Ling Wong; Magnus von Arbin; Anders von Heijne; Ann Charlotte Laska; Håkan Wallén; Denisa D Wagner; Sara Aspberg
Journal:  Thromb Res       Date:  2016-01-12       Impact factor: 3.944

Review 4.  Recombinant methionyl granulocyte colony-stimulating factor (filgrastim): a new dimension in immunotherapy.

Authors:  G Schwab; T Hecht
Journal:  Ann Hematol       Date:  1994-07       Impact factor: 3.673

5.  Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.

Authors:  Mélanie L Pastor; Céline M Laffont; Laurence Gladieff; Antonin Schmitt; Etienne Chatelut; Didier Concordet
Journal:  Pharm Res       Date:  2013-06-26       Impact factor: 4.200

6.  Laryngeal squamous cell carcinoma with ectopic production of granulocyte colony-stimulating factor and parathyroid hormone-related protein.

Authors:  Kohtaroh Tanaka; Ken-ichi Nibu
Journal:  Int J Clin Oncol       Date:  2005-06       Impact factor: 3.402

7.  Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations.

Authors:  Pawel Wiczling; Philip Lowe; Etienne Pigeolet; Frank Lüdicke; Sigrid Balser; Wojciech Krzyzanski
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  Neutrophil elastase downmodulates native G-CSFR expression and granulocyte-macrophage colony formation.

Authors:  Melissa G Piper; Pam R Massullo; Megan Loveland; Lawrence J Druhan; Tamila L Kindwall-Keller; Jing Ai; Alexander Copelan; Belinda R Avalos
Journal:  J Inflamm (Lond)       Date:  2010-01-21       Impact factor: 4.981

9.  Granulocyte-colony stimulating factor administration ameliorates liver regeneration in animal model of fulminant hepatic failure and encephalopathy.

Authors:  Stamatios E Theocharis; Lila J Papadimitriou; Zoi P Retsou; Alexandra P Margeli; Sotirios S Ninos; John D Papadimitriou
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

10.  LRG-accelerated differentiation defines unique G-CSFR signaling pathways downstream of PU.1 and C/EBPepsilon that modulate neutrophil activation.

Authors:  Jing Ai; Lawrence J Druhan; Melissa G Hunter; Megan J Loveland; Belinda R Avalos
Journal:  J Leukoc Biol       Date:  2008-02-13       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.